APA (7th ed.) Citation

TA, C., DT, J., HR, W., MHF, W., JF, P., RJ, C., . . . MF, B. (2021). Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma. Neuro-oncology practice, 8(5), 601. https://doi.org/10.1093/nop/npab034

Chicago Style (17th ed.) Citation

TA, Cook, et al. "Redo Craniotomy or Bevacizumab for Symptomatic Steroid-refractory True or Pseudoprogression Following IMRT for Glioblastoma." Neuro-oncology Practice 8, no. 5 (2021): 601. https://doi.org/10.1093/nop/npab034.

MLA (9th ed.) Citation

TA, Cook, et al. "Redo Craniotomy or Bevacizumab for Symptomatic Steroid-refractory True or Pseudoprogression Following IMRT for Glioblastoma." Neuro-oncology Practice, vol. 8, no. 5, 2021, p. 601, https://doi.org/10.1093/nop/npab034.